Usefulness of N-Terminal Pro-Brain Natriuretic Peptide to Predict Mortality in Adults With Congenital Heart Disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10315609" target="_blank" >RIV/00216208:11130/15:10315609 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10315609

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.amjcard.2015.07.070" target="_blank" >http://dx.doi.org/10.1016/j.amjcard.2015.07.070</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.amjcard.2015.07.070" target="_blank" >10.1016/j.amjcard.2015.07.070</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Usefulness of N-Terminal Pro-Brain Natriuretic Peptide to Predict Mortality in Adults With Congenital Heart Disease

Popis výsledku v původním jazyce

Natriuretic peptides are often elevated in congenital heart disease (CHD); however, the clinical impact on mortality is unclear. The aim of our study was to evaluate the prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the prediction of all-cause mortality in adults with different CHD. In this prospective longitudinal mortality study, we evaluated NT-proBNP in 1,242 blood samples from 646 outpatient adults with stable CHD (mean age 35 12 years; 345 women). Patients were followed up for 6 3 (1 to 10) years. The mortality rate was 5% (35 patients, mean age 40 14 years, 17 women). Median NT-proBNP (pg/ml) was 220 in the whole cohort, 203 in survivors, and 1,548 in deceased patients. The best discrimination value for mortality prediction was 630 pg/ml with 74% sensitivity and 84% specificity. During the follow-up, the survival rate was 65% for those with median NT-proBNP }= 630 pg/ml and 94% for NT-proBNP <630 pg/ml; p < 0.0001. There was only 1% mortality among

Název v anglickém jazyce

Usefulness of N-Terminal Pro-Brain Natriuretic Peptide to Predict Mortality in Adults With Congenital Heart Disease

Popis výsledku anglicky

Natriuretic peptides are often elevated in congenital heart disease (CHD); however, the clinical impact on mortality is unclear. The aim of our study was to evaluate the prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the prediction of all-cause mortality in adults with different CHD. In this prospective longitudinal mortality study, we evaluated NT-proBNP in 1,242 blood samples from 646 outpatient adults with stable CHD (mean age 35 12 years; 345 women). Patients were followed up for 6 3 (1 to 10) years. The mortality rate was 5% (35 patients, mean age 40 14 years, 17 women). Median NT-proBNP (pg/ml) was 220 in the whole cohort, 203 in survivors, and 1,548 in deceased patients. The best discrimination value for mortality prediction was 630 pg/ml with 74% sensitivity and 84% specificity. During the follow-up, the survival rate was 65% for those with median NT-proBNP }= 630 pg/ml and 94% for NT-proBNP <630 pg/ml; p < 0.0001. There was only 1% mortality among

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American Journal of Cardiology

ISSN

0002-9149

e-ISSN

—

Svazek periodika

116

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

1425-1430

Kód UT WoS článku

000364621400018

EID výsledku v databázi Scopus

2-s2.0-84944315179